Business Description
Kintara Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US49720K2006
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.09 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38.4 | |||||
3-Year EPS without NRI Growth Rate | 37.7 | |||||
3-Year FCF Growth Rate | 41.8 | |||||
3-Year Book Growth Rate | 33.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.46 | |||||
9-Day RSI | 59.87 | |||||
14-Day RSI | 57.68 | |||||
6-1 Month Momentum % | -97.92 | |||||
12-1 Month Momentum % | -96.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.63 | |||||
Quick Ratio | 0.63 | |||||
Cash Ratio | 0.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -94.7 | |||||
Shareholder Yield % | -45.17 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -592.94 | |||||
ROA % | -220.52 | |||||
ROIC % | -1104.97 | |||||
ROC (Joel Greenblatt) % | -1104.97 | |||||
ROCE % | -549.12 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.45 | |||||
EV-to-EBITDA | -1.46 | |||||
EV-to-Forward-Revenue | 0.85 | |||||
EV-to-FCF | -2.28 | |||||
Earnings Yield (Greenblatt) % | -68.97 | |||||
FCF Yield % | -116.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Kintara Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -5.547 | ||
Beta | 0.64 | ||
Volatility % | 119.56 | ||
14-Day RSI | 57.68 | ||
14-Day ATR (€) | 0.01522 | ||
20-Day SMA (€) | 0.11228 | ||
12-1 Month Momentum % | -96.87 | ||
52-Week Range (€) | 0.07 - 4.68 | ||
Shares Outstanding (Mil) | 39.04 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kintara Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kintara Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Kintara Therapeutics Inc Frequently Asked Questions
What is Kintara Therapeutics Inc(STU:3DMA)'s stock price today?
When is next earnings date of Kintara Therapeutics Inc(STU:3DMA)?
Does Kintara Therapeutics Inc(STU:3DMA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |